PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33674622-5	2021	Lenvatinib strongly inhibited the phosphorylation of FRS2 and ERK, the downstream signaling molecules of FGFR4, compared with sorafenib and regorafenib.	lenvatinib	0-10	fibroblast growth factor receptor substrate 2	Homo sapiens	53-57	
30944079-7	2019	Lenvatinib and E7090 decreased phosphorylation of downstream molecules of the FGF signaling pathway (such as FRS2, Erk, and p38 MAPK), and induced PARP cleavage, even under limited nutrients.	lenvatinib	0-10	fibroblast growth factor receptor substrate 2	Homo sapiens	109-113	
25295214-6	2014	Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2.	lenvatinib	87-97	fibroblast growth factor receptor substrate 2	Homo sapiens	165-169	
29733511-5	2018	Lenvatinib suppressed phosphorylation of FRS2, a substrate of FGFR1-4, in these cells in a concentration-dependent manner.	lenvatinib	0-10	fibroblast growth factor receptor substrate 2	Homo sapiens	41-45	
29733511-6	2018	Lenvatinib inhibited in vivo tumor growth in Hep3B2.1-7 and SNU-398 xenografts and decreased phosphorylation of FRS2 and Erk1/2 within the tumor tissues.	lenvatinib	0-10	fibroblast growth factor receptor substrate 2	Homo sapiens	112-116